



Cite this: RSC Adv., 2018, 8, 17389

Monascus pigment rubropunctatin derivative FZU-H reduces A β (1-42)-induced neurotoxicity in Neuro-2A cells

Yunquan Zheng, ^{*ac} Qisheng Pan,^a Liuda Mo,^a Wenyi Zhang,^a Yunjian Duan,^a Chengqun Chen,^b Haijun Chen, ^{*a} Yanghao Guo,^c Xianai Shi^c and Jianmin Yang

Alzheimer's disease (AD) is an extremely complex disease, characterized by several pathological features including oxidative stress and amyloid- β (A β) aggregation. Blockage of A β -induced injury has emerged as a potential therapeutic approach for AD. Our previous efforts resulted in the discovery of *Monascus* pigment rubropunctatin derivative FZU-H with potential neuroprotective effects. This novel lead compound significantly diminishes toxicity induced by A β (1-42) in Neuro-2A cells. Our further mechanism investigation revealed that FZU-H inhibited A β (1-42)-induced caspase-3 protein activation and the loss of mitochondrial membrane potential. In addition, treatment of FZU-H was proven to attenuate A β (1-42)-induced cell redox imbalance and Tau hyperphosphorylation which caused by okadaic acid in Neuro-2A cells. These results indicated that FZU-H shows promising neuroprotective effects for AD.

Received 18th March 2018

Accepted 8th May 2018

DOI: 10.1039/c8ra02365d

rsc.li/rsc-advances

1. Introduction

Alzheimer's disease (AD), characterized by abundant senile plaques (SP) comprised of the amyloid-beta (A β) peptide and neurofibrillary tangles (NFT) formed from the highly phosphorylated Tau protein, is the leading cause of dementia in the elderly.¹⁻³ *In vitro* and *in vivo* studies demonstrated that A β peptide or A β peptide fragments induced the disruption of the mitochondrial membrane,^{4,5} resulting in the production of reactive oxygen species (ROS)⁶⁻⁸ and apoptosis of neurons directly or indirectly.⁹⁻¹² Moreover, oxidative stress has an important function in the early stages of AD.^{13,14} Especially, overexpression of superoxide dismutase (SOD) in animals showed neuroprotective effects in A β -induced AD and neurotoxicity.¹⁵ On the other hand, several studies suggested that hyperphosphorylated Tau protein also caused mitochondrial dysfunction and induced oxidative stress.^{16,17} In addition, hyperphosphorylated Tau protein also exerted a neurotoxic effect when expressed in neuronal cells, *via* induction of chromatin condensation, DNA fragmentation, and caspase-3 activation, and finally resulted in a region-specific neurodegeneration.¹⁸⁻²⁰ Therefore, inhibition of A β deposition,

Tau phosphorylation, and oxidative stress is an important goal to alleviate the occurrence of AD.

Red fermented rice (also called red yeast rice) has been widely used in East Asia for centuries as a source of folk medicine to improve food digestion and blood circulation.^{21,22} Several significant biological activities of red fermented rice were reported, including regulation of plasma cholesterol levels,²³⁻²⁵ reduction of blood glucose levels in diabetic rats^{26,27} and improvements of the memory and learning ability in A β -infused rats.^{28,29} Various metabolites were identified from the *Monascus* species, including azaphilones,³⁰⁻³² furanoisophthalides, amino acids,^{33,34} polyketides,²² and fatty acids.³⁵ However, the clear active ingredient in red fermented rice and the mechanisms of the function to repress A β peptide-induced neurotoxicity was largely undefined.

In recent years, it has been reported that azaphilones exhibited a wide range of biological activities including antimicrobial, antiviral, anticancer, antioxidant and anti-inflammatory activities.^{36,37} In particular, lovastatin and simvastatin (Fig. 1), one series of azaphilones, can reduce the production of A β fragments.^{38,39} In addition, azaphilones has been reported to exhibit anti-inflammatory and antioxidative effects which were regarded as the key factors against A β -induced neurotoxicity. These results indicated that it was reasonable to explore the neuroprotective effects of azaphilones against A β -induced apoptotic death and to investigate the associated potential mechanisms. In our continuing effort to develop potential therapeutic agents for AD, a series of rubropunctatin derivatives were designed, synthesized, and biological evaluated. Among them, compound FZU-H (Fig. 1)

^aCollege of Chemistry, Fuzhou University, 2 Xueyuan Road, Fuzhou 350116, Fujian 350108, China. E-mail: yunquanzheng@fzu.edu.cn; chenhaij@gmail.com; Fax: +86-591-22866237; Tel: +86-591-22866234

^bDepartment of Chemical Engineering, Fuzhou University, Zhicheng College, 523 Gongye Road, Fuzhou 350002, China

^cFujian Key Laboratory of Medical Instrument and Pharmaceutical Technology, Fuzhou University, 2 Xueyuan Road, Fuzhou 350116, China






Fig. 1 Chemical structures of lovastatin, simvastatin, rubropunctatin and rubropunctatin derivative FZU-H.

displayed significant neuroprotective effect. In this work, we further investigated the potential mechanisms of how FZU-H protected the neuronal cells against A β (1-42)-induced neurotoxicity and related signaling pathways.

2. Experimental section

2.1 General

Neuro-2A cell line was purchased from the Cell Resource Center (Beijing, China). Minimum Essential Medium Eagles with Earle's Balanced Salts (MEM-EBSS) and fetal bovine serum (FBS) were obtained from HyClone (Logan, UT, USA). Mouse A β (1-42) was purchased from GL Biochem (Shanghai, China). Hexa-fluoroisopropanol (HFIP) was purchased from Aladdin (Shanghai, China). 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), dimethylsulfoxide (DMSO) and okada acid (OA) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The Annexin V FITC kit, normal/apoptotic/necrotic cell detection kit, reactive oxygen species assay kit, and the total superoxide dismutase assay kit were obtained from KeyGEN biotech (Nanjing, China). The Caspase 3 activity assay kit, mitochondrial membrane potential detection kit (JC-1), RIPA Buffer and BCA Protein Assay Kit were obtained from Beyotime (Haimen, China). β -Actin rabbit monoclonal antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), phospho-Tau pThr205 antibody was purchased from Pierce Biotechnology (Pierce, USA). Anti-Tau (Phospho S396) antibody, anti-Tau (Phospho S202) antibody and HRP-conjugated anti-rabbit IgG polyclonal secondary antibody were purchased from Abcam Ltd. (New Territories, Hong Kong). All chemicals used were of analytical grade.

2.2 Purification and identification of FZU-H

Monascus azaphilone rubropunctatin (above 98.5% purity) was purified from red mold rice (Fuzhou Longixin Biological Product Company) by High-speed Counter-current Chromatography (Zheng *et al.* 2010). Rubropunctatin was reduced by sodium borohydride to give the compound FZU-H (above 98.5% purity), which was identified by HPLC-MS and NMR spectroscopy. The detailed preparation and purification procedure was as follow: to a solution of *Monascus* azaphilone rubropunctatin (354 mg, 1 mmol) in CH₃OH (10 mL) was added a solution of NaBH₄ (112 mg, 3 mmol) in CH₃OH (20 mL). The resulting solution was stirred at room temperature for 12 h (the progress of the reaction was monitored by TLC). Then H₂O (5 mL) and CHCl₃ (15 mL) were added. The combined organic phases were washed with brine, dried (anhyd Na₂SO₄), filtered, and concentrated. The residue was purified by column chromatography on silica gel, eluting with CH₃OH-CHCl₃ (1 : 1, v/v), to give FZU-H; yield: 249 mg (70.3%). An Agilent 1100 series ion trap LC/MS systems (Agilent, USA) was used to determine the molecular weight. The mass spectrometer was equipped with an electrospray ionization (ESI) source. The ESI conditions were as follows: capillary voltage, 3.5 kV; nebulizer pressure, 40 psi; drying gas flow, 10 mL min⁻¹; temperature, 350 °C. The mass range was from *m/z* 100 to 400.

¹H and ¹³C NMR spectra were measured with an Inova-500M NMR spectrometer (Varian, USA) in CDCl₃ operating at 500 MHz for ¹H NMR and at 125 MHz for ¹³C NMR. Tetramethylsilane (TMS) was employed as an internal standard.

FZU-H: ESI-MS, *m/z* 357.1 [M + H]⁺; ¹H NMR (CDCl₃, 500 MHz), δ 0.87 (3H, t, H-19), 1.304–1.335 (4H, m, H-17–18), 1.55 (3H, s, H-10), 1.61 (2H, m, H-16), 1.93 (3H, d, H-13), 2.14 (1H,

brs, O-H), 2.93 (2H, m, H-15), 4.37 (1H, s, H-4), 6.01 (1H, d, H-11), 6.13 (1H, s, H-8), 6.57 (1H, dq, H-12), 6.88 (1H, s, H-9), 6.97 (1H, s, H-5); ^{13}C NMR (CDCl₃, 125 MHz), δ 13.963 (C-19), 18.735 (C-10), 22.569 (C-13), 23.380 (C-18), 28.283 (C-16), 31.338 (C-17), 41.533 (C-15), 48.928 (C-4), 67.650 (C-3a), 104.173 (C-8), 104.377 (C-4a), 115.560 (C-9), 116.293 (C-11), 118.666 (C-1), 136.345 (C-12), 139.081 (C-5), 141.582 (C-8a), 155.661 (C-7), 169.193 (C-2), 179.257 (C-9a), 190.772 (C-14).

2.3 Cell culture and drug preparation

Neuro-2A mouse neuroblastoma cells were grown and maintained in MEM-EBSS media containing 10% FBS, 2 mM glutamine, 40 U mL⁻¹ gentamicin at 37 °C under 5% CO₂. FZU-H was dissolved in sterile water, and stored in the dark at -20 °C until used. Preparation of A β (1-42) peptide was performed following the manufacturer recommendations. The A β (1-42) peptide was initially dissolved to 1 mM in HFIP and separated into aliquots in sterile microcentrifuge tubes. HFIP was removed under vacuum in a freeze dryer (FDU-1200, Shimadzu Instruments, Japan), and the peptide film was stored dessicated at -80 °C. When used, the peptide was first resuspended in dry DMSO to a concentration of 5 mM, and then 10 mM HCl was added to bring it to a final concentration of 100 μ M and incubated for 24 h at 37 °C.

2.4 MTT assay for cell viability

Neuro-2A cell viability was measured using the MTT assay. Briefly, cells (1×10^5 cells per mL) were plated into 96-well plates in a total volume of 100 μ L of culture medium and then cultured for 12 h at 37 °C, 5% CO₂. After exposure to different concentration of FZU-H and A β (1-42) for 24 h, 10 μ L MTT solution was added to each well and the plates were incubated for additional 4 h at 37 °C. To achieve solubilization of the formazan crystal formed in viable cells, the medium containing MTT was aspirated off and 150 μ L of DMSO was added to each well. The absorbance was read at 570 nm using SH-1000 microplate reader (Corona Electric, Hitachinaka, Japan).

2.5 Cell survival assay (fluorescent staining)

Neuro-2A cells were analyzed in the presence of acridine orange and ethidium bromide staining (AO/EB staining). Neuro-2A cells were plated into six well plates at a density of 5×10^5 cells per mL and incubated for 12 h. After exposure to different concentration of FZU-H and A β (1-42) for 24 h, the cells were harvested by trypsin without EDTA and washed with phosphate-buffered saline (PBS). Dye mixture (1 mL) was mixed with 25 μ L of cell suspension (5×10^5 cells per mL) on a clean microscope slide and then immediately examined by fluorescence microscopy (Olympus IX71, Tokyo, Japan) at 400 \times magnification.

2.6 Apoptosis assay

To detect early apoptosis and late apoptosis/necrosis, the cells were stained with FITC-conjugated Annexin V and PI after treatment with different concentration of FZU-H and 10 μ M of A β (1-42) for 24 h. The cells were harvested by trypsin without

EDTA and washed with PBS before being resuspended in 500 μ L of binding buffer (1 M Hepes and 2 M NaCl, pH 7.0). 5 μ L of Annexin V-FITC and 5 μ L PI were added and incubated for 15 min at room temperature in the dark. Neuro-2A cells (1×10^4) were analyzed immediately by a Coulter EPICS XL flow cytometer (Beckman Coulter Co. Ltd., FL, USA).

2.7 Measurement of caspase-3 activity

The activity of caspase-3 was determined by using the Caspase-3 activity kit according to the manufacturer's protocol. To evaluate the activity of caspase-3, cell lysates were prepared after their respective treatment. Assays were performed on 96-well plates by incubating 10 μ L of cell lysate per sample in 80 μ L reaction buffer containing 10 μ L caspase-3 substrate acetyl-Asp-Glu-Val-Asp *p*-nitroanilide (Ac-DEVD-*p*NA, 2 mM). Lysates were incubated at 37 °C for 2 h and then measured with a microplate reader (Corona Electric, Hitachinaka, Japan) at an absorbance of 405 nm.

2.8 Determination of mitochondrial membrane potential

Mitochondrial transmembrane potential was measured by using JC-1 dye, a fluorochrome which exclusively emits within the spectrum of green light and accumulates in the mitochondrial matrix under the influence of mitochondrial transmembrane potential. JC-1 easily penetrates cells and healthy mitochondria. A green fluorescent JC-1 probe exists as a monomer at low membrane potentials; however, at higher potentials, JC-1 forms red-fluorescent 'J-aggregates'. Neuro-2A cells (3×10^5 cells per mL) were cultured in 6-well plates (2 mL per well) overnight and then incubated with different concentration of FZU-H and 10 μ M of A β (1-42) for 24 h. Neuro-2A cells were collected by trypsinization and incubated with medium containing JC-1 for 20 min at 37 °C. Then the cells were washed with PBS, resuspended in 0.5 mL buffer, and analyzed with Epics XL flow cytometer (Beckman-Coulter, Fullerton, CA) at FL1 (529 nm) for green fluorescence and FL2 (590 nm) for red fluorescence.

2.9 Measurement of ROS

Generation of ROS was assessed by DCFH-DA, an oxidation-sensitive fluorescent probe. An increase in fluorescence intensity is used to quantify the generation of net intracellular ROS. After treatment of cells with different concentrations, the cells were incubated with 10 μ M DCFH-DA at 37 °C for 30 min and then washed twice with PBS. The fluorescence intensity of DCF was measured by Epics XL flow cytometer. ROS generation was quantified by the median fluorescence intensity of 1×10^4 cells.

2.10 Measurement of SOD activity

The activity of SOD was measured following the manufacturer's manual with subtle changes. Briefly, the cells were lysated after their respective treatment. The homogenate was centrifuged at 12 000 rpm for 8 min at 4 °C to precipitate insoluble material. The supernatant was assayed for SOD activity following the manufacturer's manual and the absorbance at 550 nm was read



with a UV-1800 spectrophotometer (Shimadzu Corporation, Tokyo, Japan).

2.11 Western blotting assay

Cells (1×10^7 cells) in different treatment groups were collected and washed with PBS. After centrifugation, sedimented cells were lysed by vigorous shaking in RIPA Lysis Buffer (Beyotime Institute of Biotechnology, Haimen, China) with PMSF for 20 min at 4 °C, and then centrifuged again at 4 °C, 12 000 rpm for 15 min. The supernatant was separated and collected for protein analysis and the protein concentration was determined by using the BCA protein assay kit (Beyotime Institute of Biotechnology, Haimen, China). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis was performed by loading equal amounts of proteins per lane. The gels were then transferred to PVDF membranes (Millipore) and blocked with 5% BSA in tris(hydroxymethyl)aminomethane–NaCl–Tween20 (TBST) buffer at 4 °C with slightly shaking for 2 h. Then the membranes were incubated with rabbit anti-Tau(phospho ser396) antibody (1 : 25 000), anti-Tau(phospho ser202) antibody (1 : 10 000), anti-Tau(phospho-thr205) antibody (1 : 750) or anti- β -actin antibody (1 : 2000) at 4 °C overnight. The secondary antibodies conjugated with horseradish peroxidase at 1 : 15 000 dilutions for 2 h at room temperature. The detection and quantification of specific bands were performed using a fluorescence scanner (Molecular Imager ChemiDoc XRS System, Bio-Rad, Hercules, CA).

2.12 Statistical analysis

The results were expressed as the mean \pm standard deviation (SD) from three independent experiments. Statistical analysis was performed using Student's *t* test. The differences were considered significant for $p < 0.05$ (*), and $p < 0.01$ indicated very significant differences (**).

3. Results and discussion

3.1 FZU-H ameliorated A β (1-42)-induced neurotoxicity

To assess A β (1-42)-induced Neuro-2A cells death, the cells were analyzed on MTT assay. As shown in Fig. 2, when Neuro-2A cells were exposed to A β (1-42) at different concentration (1, 5, 10 and 15 μ M) for 24 h, $4.2 \pm 1.6\%$, $24.2 \pm 3.3\%$, $34.5 \pm 3.0\%$ and $48.8 \pm 2.0\%$ of neuronal cell death was observed, respectively. Therefore, for the following experiments, the concentration of 10 μ M was used for the determination of A β (1-42)-induced Neuro-2A cell damage.

The cell viability was employed to observe the protective effect of FZU-H on A β (1-42)-induced neurotoxicity in Neuro-2A cells. As illustrated in Fig. 2, treatment of FZU-H significantly increased Neuro-2A cell viability in a dose-dependent manner, indicating that azaphilone derivative FZU-H exhibited predominant neuroprotective effect against A β (1-42)-induced injury.




Fig. 2 Effect of FZU-H on cell viability in A β (1-42)-induced cytotoxicity. Each bar represents the mean \pm SD from six independent experiments ($n = 6$, * $p < 0.05$ and ** $p < 0.01$ versus control group; # $p < 0.05$ versus the group treated A β (1-42) alone).

3.2 Microscopic analysis and fluorescence microscopy to observe morphological characteristics of Neuro-2A cells

As shown in Fig. 3, A β (1-42) treatment caused the significant damage of Neuro-2A cells (Fig. 3B) in comparison to the control (Fig. 3A). While the addition of 50 μ M FZU-H can protect A β (1-42)-induced damage (Fig. 3C). We next used AO/EB double staining to detect the apoptotic Neuro-2A cells. The results are represented in Fig. 3D and E. The figures showed that the A β (1-42) treated group (Fig. 3E) induced apoptosis after 24 h of incubation at 10 μ M concentration compared with the control group without A β (1-42) treatment (Fig. 3D), and cells showed changes in cellular morphology including chromatin condensation and fragmented nuclei. Cells stained green represented viable cells, whereas yellow staining represented early apoptotic cells, and reddish or orange staining represented late apoptotic cells. As shown in Fig. 3F, Neuro-2A cells treated with 50 μ M FZU-H can significantly prevent the changes of cellular morphology induced by A β (1-42).

3.3 Protective effect of FZU-H on A β (1-42)-induced apoptosis of Neuro-2A cells

To determine the apoptotic response in Neuro-2A cells, we initially detected the effect of FZU-H treatment using Annexin/PI staining by flow cytometry. As shown in Fig. 4, there was a significant difference between the FZU-H treatment groups and the A β (1-42) group. The ratio of living cells, as evidenced by Annexin V/PI negativity in the A β (1-42) group (73.7%), was significantly lower than that of the control group (95.4%). The percentage of apoptotic cells both control group and A β (1-42) treatment group were 3.6% (Fig. 4A) and 19.2% (Fig. 4B). While the percentage of FZU-H treatment group was 11.4% (10 μ M, Fig. 4C), 10.8% (50 μ M, Fig. 4D) and 6.0% (100 μ M, Fig. 4E). The results indicated that each treatment of FZU-H can reduce A β (1-42)-induced apoptotic cell death in a dose-dependent manner.






Fig. 3 Effect of FZU-H on morphological characteristics of Neuro-2A cells. Morphological studies by inverted microscope at actual magnification 400 \times ; (A). Normal control group; (B). A β (1-42) treatment group; (C). A β (1-42) + 50 μ M FZU-H treatment group. Morphological observation with AO/EB staining at actual magnification 100 \times ; (D). Normal control group; (E). A β (1-42) treatment group; (F). A β (1-42) + 50 μ M FZU-H treatment group.

3.4 FZU-H inhibits A β (1-42)-induced caspase-3 protein activation

Caspase-3 activity were determined by a colorimetric assay based on the ability of caspase-3 to change Ac-DEVD-pNA into

a yellow formazan product (*p*-nitroaniline, pNA). Under the exposure of A β (1-42) at 10 μ M, caspase-3 activity significantly increased (182.5%), in comparison to the control without A β (1-42) treatment (Fig. 5). FZU-H significantly blocked the A β (1-42)-induced increase of caspase-3 activity. These results implicated




Fig. 4 Effect of FZU-H on A β (1-42)-induced apoptosis by flow cytometry; (A). Normal control group; (B). A β (1-42) treatment group; (C). A β (1-42) + 10 μ M FZU-H treatment group; (D). A β (1-42) + 50 μ M FZU-H treatment group; (E). A β (1-42) + 100 μ M FZU-H treatment group. This is a representative experiment of three independent experiments.






Fig. 5 Inhibitory effect of FZU-H on A β (1-42)-induced caspase-3 expression in cultured Neuro-2A cells. The cells were incubated with 10 μ M A β (1-42) and different concentration of H (10, 50 and 100 μ M) for 24 h. The relative activities of caspase-3 shown are calculated from the average of three experiments. Each value was expressed as the ratio of caspase-3 activation level to control level, and the value of control was set to 100 ($n = 3$, * $p < 0.05$ and ** $p < 0.01$ compared with normal control group; # $p < 0.05$ and ## $p < 0.01$ compared with A β (1-42) treatment group).

that A β (1-42)-induced apoptosis occurs through the activation of common executors of apoptosis such as caspase-3, and FZU-H inhibited caspase-3 activity appeared to participate in preventing A β (1-42)-induced apoptosis pathway.

3.5 Effect of FZU-H on cellular ROS levels

When Neuro-2A cells were treated with 10 μ M A β (1-42) for 24 h, cells were harvested to evaluate ROS production and detected by flow cytometry. We found that the fluorescence intensity significantly increased from 6.0 to 22.3 by using DCFH-DA assay. However, treatment with different concentration of FZU-H decreased the ROS production in a dose-dependent manner (Fig. 6). The results suggest that ROS is generated by A β (1-42) treatment and FZU-H may act as a potential protective agent to prevent apoptosis by attenuating A β (1-42)-induced ROS production.

3.6 Effect of FZU-H in A β (1-42)-induced SOD activity

The activity of SOD in Neuro-2A cells treated with A β (1-42) and different concentrations of FZU-H are shown in Fig. 7. The relative activity of SOD in cells treated with 10 μ M A β (1-42) for 24 h was significantly lower than that of the control. Whereas, after supplemented with FZU-H (10, 50, and 100 μ M), an evident elevation of SOD activity was detected in Neuro-2A cells, and the




Fig. 6 Effect of FZU-H on A β (1-42)-induced ROS overproduction. After treatment of cells with different concentration of FZU-H and 10 μ M A β (1-42) for 24 h, the cells were incubated with 10 μ M DCFH-DA at 37 °C for 30 min and then washed twice with PBS. The fluorescence intensity of DCF was measured at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Relative fluorescence intensity obtained from three independent experiments ($n = 3$, * $p < 0.05$ and ** $p < 0.01$ compared with normal control group; # $p < 0.05$ and ## $p < 0.01$ compared with A β (1-42) treatment group).






Fig. 7 Effects of FZU-H on the inhibition of A β (1-42)-induced oxidative stress ($n = 3$, * $p < 0.05$ and ** $p < 0.01$ compared with normal control group; # $p < 0.05$ and ## $p < 0.01$ compared with A β (1-42) treatment group).

treatment of 100 μ M FZU-H displayed a significant increase of 13.3% in comparison to the only A β (1-42) treatment group.

3.7 Effect of FZU-H on mitochondrial membrane potential

The changes of mitochondrial membrane potential induced by FZU-H were determined using JC-1 as a fluorescent probe. At high mitochondrial membrane potential, JC-1 forms aggregates, which exhibits red fluorescence. At low mitochondrial membrane potential, JC-1 forms monomers, which exhibits green fluorescence. The changes of mitochondrial membrane potential are shown in Fig. 8. Results are expressed as a ratio of red/green intensities.⁶¹ The decrease of the ratio of red fluorescence and green fluorescence showed the impaired of mitochondrial membrane potential. These results suggested that FZU-H inhibited the loss of mitochondrial membrane potential caused by A β (1-42) in Neuro-2A cells.

3.8 FZU-H inhibits hyperphosphorylation of Tau caused by okadaic acid in Neuro-2A cells

After OA treatment for 24 h in the presence or absence of FZU-H, we measured Ser396, ser202 and thr205 Tau phosphorylation by Western blot. As shown in Fig. 9, the treatment of Neuro-2A cells with 30 nM OA for 24 h significantly increased the expression of phosphorylated forms of Tau protein compared with the control group. After treatment with different concentration of FZU-H, the relative quantity of Tau exhibited different degree of reduction. In addition, treatment of 100 μ M FZU-H significantly reduced Tau phosphorylation induced by OA on these three residues.

4. Discussion

AD is pathologically characterized by the presence of A β amyloid plaques and neurofibrillary tangles, as well as the selective loss of neurons and synaptic connections.⁴⁰ A β plays




Fig. 8 Effect of FZU-H on mitochondrial membrane potential. Mitochondrial transmembrane potential was measured by JC-1 staining. Epics XL flow cytometer at FL1 (529 nm) for green fluorescence and FL2 (590 nm) for red fluorescence (EX = 488 nm). The results were expressed as the mean \pm standard deviation (SD) from three independent experiments (* $p < 0.05$ and ** $p < 0.01$ compared with normal control group; # $p < 0.05$ and ## $p < 0.01$ compared with A β (1-42) treatment group).

the decisive role in the pathogenesis of AD. It is clear that A β -induced neurotoxicity has been attributed to cell necrotic and apoptotic,^{9,41,42} activation of caspase-3,²⁶ the generation of ROS,⁴³ oxidative stress⁴⁴ and inflammation with the resultant axon transport dysfunctions and cognitive decline.⁴⁵ According to this study, treatment of FZU-H was certainly proven to attenuate A β (1-42)-induced cell death and apoptosis, redox imbalance and OA-induced Tau phosphorylation.

The cell viability and fluorescence staining in this work were employed to observe the protective effect of FZU-H on A β (1-42)-induced neurotoxicity in Neuro-2A cells. The results indicated that FZU-H significantly attenuated A β (1-42)-induced cell apoptosis and morphology damage. In Annexin/PI staining study, when the cells were treated with 10 μ M of A β , the percentage of apoptotic cells were increased to 19.2%. After the addition of FZU-H, the apoptosis populations decreased dose-dependently. These results suggest that FZU-H can protect Neuro-2A cells against A β (1-42)-induced apoptosis.

Caspases are cysteine-dependent aspartate-specific proteases critically involved in apoptosis.⁴⁶ Activation of caspase-3 is an important step in the execution phase of apoptosis and inhibition of this pathway blocks cell apoptosis.⁴⁷ Among the caspase family, consist of more than 10 homologues, caspase-3 has been suggested to play an important role in A β -induced apoptosis.⁴⁸ In this study, we found that treatment of A β (1-42) increased caspase-3 activity of Neuro-2A cells, and FZU-H significantly blocked this signaling pathway.

Studies in non-neuronal cells have suggested that a fall in mitochondrial membrane potential is one of the earliest events in apoptosis.⁴⁹ Mitochondrial abnormalities have been identified in a large proportion of neurodegenerative diseases.^{50,51} In this work, we found that the deposit of A β protein is thought to be toxic to neurons possibly *via* induction of mitochondrial membrane potential, our results suggested that FZU-H abolished A β -induced cell death and increased mitochondrial




Fig. 9 Western blot analysis of the effects of OA and FZU-H on the expression of Tau in Neuro-2A cells. β -Actin was used as an internal control. The relative quantity obtained by Bio-Rad Image Lab software ($n = 3$, * $p < 0.05$ and ** $p < 0.01$ compared with normal control group; # $p < 0.05$ and ## $p < 0.01$ compared with A β (1-42) treatment group).

membrane potential in Neuro-2A cells, indicating that mitochondrial membrane potential elevation is an associated phenomenon induced by A β that can be rescued by FZU-H.

AD is a complex disease that involves a multitude of dysfunctional processes. Oxidative damage in AD may be a direct result of A β . Several studies demonstrated that A β -induced apoptosis was associated with ROS production,⁵²⁻⁵⁴ including the superoxide (O_2^-), hydroxyl radicals and hydrogen peroxide (H_2O_2).^{55,56} Many studies revealed that A β -induced cell damage was due to the occurrence of oxidative stress.^{15,57} In this work, we demonstrated that A β significantly increased the ROS production in the Neuro-2A cells and pretreatment with FZU-H ameliorates this change in a dose-dependent manner. In addition, we observed that treatment with FZU-H can decrease the A β -induced oxidative damage.

It is worth pointing out that OA, a widely used reagent for Tau protein hyperphosphorylation, has been previously

reported as a specific inhibitor of protein phosphatase 2A (PP2A),⁵⁸⁻⁶⁰ which is an important phosphatase responsible for Tau protein phosphorylation in the neurodegenerative progress. Herein, we revealed that FZU-H significantly prevented OA-induced hyperphosphorylation of Tau protein (at Thr205, Ser396 and Ser202 sites).

5. Conclusions

A β -induced apoptotic, highly phosphorylated Tau protein and excessive generation of ROS play decisive role in the pathogenesis of AD. Compound FZU-H could ameliorate the apoptosis of Neuro-2A cells induced by A β (1-42), and the anti-apoptosis ability enhanced significantly with the increase of drug concentration assayed by caspase 3 activity, mitochondrial membrane potential and Annexin V-FITC/PI staining experiments using flow cytometry. FZU-H significantly prevented OA-

induced hyperphosphorylation of Tau protein, alleviated the decrease of SOD activity and inhibited the elevation of intracellular ROS level. Taken together, FZU-H shows promising neuroprotective effects.

Conflicts of interest

The authors declare that they have no conflict of interest. This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was obtained from all individual participants included in the study.

Acknowledgements

This work was supported by Natural Science Foundation of Fujian Province of China (No. 2017J01854), Fujian Province Young and Middle-aged Teacher Education Research Project (JAT160655), and the Marine High-tech Industry Development Special Project of Fujian Province of China (Min Marine High-tech [2015]01).

References

- 1 D. L. Price, R. E. Tanzi, D. R. Borchelt and S. S. Sisodia, *Annu. Rev. Genet.*, 1998, **32**, 461–493.
- 2 M. Goedert and M. G. Spillantini, *Science*, 2006, **314**, 777–781.
- 3 O. Klementieva, E. Aso, D. Filippini, N. Benseny-Cases, M. Carmona, S. Juves, D. Appelhans, J. Cladera and I. Ferrer, *Biomacromolecules*, 2013, **14**, 3570–3580.
- 4 C. S. Casley, J. M. Land, M. A. Sharpe, J. B. Clark, M. R. Duchen and L. Canevari, *Neurobiol. Dis.*, 2002, **10**, 258–267.
- 5 A. Eckert, U. Keil, C. A. Marques, A. Bonert, C. Frey, K. Schussel and W. E. Muller, *Biochem. Pharmacol.*, 2003, **66**, 1627–1634.
- 6 M. T. Lin and M. F. Beal, *Nature*, 2006, **443**, 787–795.
- 7 D. A. Butterfield, T. Reed, S. F. Newman and R. Sultana, *Free Radical Biol. Med.*, 2007, **43**, 658–677.
- 8 T. Schilling and C. Eder, *J. Cell. Physiol.*, 2011, **226**, 3295–3302.
- 9 D. T. Loo, A. Copani, C. J. Pike, E. R. Whittemore, A. J. Walencewicz and C. W. Cotman, *Proc. Natl. Acad. Sci. U. S. A.*, 1993, **90**, 7951–7955.
- 10 C. Behl, J. B. Davis, F. G. Klier and D. Schubert, *Brain research*, 1994, **645**, 253–264.
- 11 H. Satoi, H. Tomimoto, R. Ohtani, T. Kitano, T. Kondo, M. Watanabe, N. Oka, I. Akguchi, S. Furuya, Y. Hirabayashi and T. Okazaki, *J. Neurosci.*, 2005, **130**, 657–666.
- 12 P. Picone, R. Carrotta, G. Montana, M. R. Nobile, P. L. San Biagio and M. Di Carlo, *Biophys. J.*, 2009, **96**, 4200–4211.
- 13 A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, E. K. Balraj, P. K. Jones, H. Ghanbari, T. Wataya, S. Shimohama, S. Chiba, C. S. Atwood, R. B. Petersen and M. A. Smith, *J. Neuropathol. Exp. Neurol.*, 2001, **60**, 759–767.
- 14 A. Nunomura, R. J. Castellani, X. Zhu, P. I. Moreira, G. Perry and M. A. Smith, *J. Neuropathol. Exp. Neurol.*, 2006, **65**, 631–641.
- 15 A. Clausen, X. Xu, X. Bi and M. Baudry, *J. Alzheimer's Dis.*, 2012, **30**, 183–208.
- 16 D. C. David, S. Hauptmann, I. Scherping, K. Schuessel, U. Keil, P. Rizzu, R. Ravid, S. Drose, U. Brandt, W. E. Muller, A. Eckert and J. Gotz, *J. Biol. Chem.*, 2005, **280**, 23802–23814.
- 17 C. Ballatore, V. M. Lee and J. Q. Trojanowski, *Nat. Rev. Neurosci.*, 2007, **8**, 663–672.
- 18 T. Fath, J. Eidenmuller and R. Brandt, *J. Neurosci.*, 2002, **22**, 9733–9741.
- 19 N. Shahani, S. Subramaniam, T. Wolf, C. Tackenberg and R. Brandt, *J. Neurosci.*, 2006, **26**, 6103–6114.
- 20 H. L. Li, H. H. Wang, S. J. Liu, Y. Q. Deng, Y. J. Zhang, Q. Tian, X. C. Wang, X. Q. Chen, Y. Yang, J. Y. Zhang, Q. Wang, H. Xu, F. F. Liao and J. Z. Wang, *Proc. Natl. Acad. Sci. U. S. A.*, 2007, **104**, 3591–3596.
- 21 C. L. Lee, T. Y. Tsai, J. J. Wang and T. M. Pan, *Appl. Microbiol. Biotechnol.*, 2006, **70**, 533–540.
- 22 J. Ma, Y. Li, Q. Ye, J. Li, Y. Hua, D. Ju, D. Zhang, R. Cooper and M. Chang, *J. Agric. Food Chem.*, 2000, **48**, 5220–5225.
- 23 Y. Kohama, S. Matsumoto, T. Mimura, N. Tanabe, A. Inada and T. Nakanishi, *Chem. Pharm. Bull.*, 1987, **35**, 2484–2489.
- 24 J. Shepherd, S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer, P. W. MacFarlane, J. H. McKillop and C. J. Packard, *N. Engl. J. Med.*, 1995, **333**, 1301–1307.
- 25 C. L. Lee, Y. H. Kung, C. L. Wu, Y. W. Hsu and T. M. Pan, *J. Agric. Food Chem.*, 2010, **58**, 9013–9019.
- 26 J. H. Su, M. Zhao, A. J. Anderson, A. Srinivasan and C. W. Cotman, *Brain research*, 2001, **898**, 350–357.
- 27 Y. C. Shi and T. M. Pan, *J. Agric. Food Chem.*, 2010, **58**, 7634–7640.
- 28 C. L. Lee, T. F. Kuo, C. L. Wu, J. J. Wang and T. M. Pan, *J. Agric. Food Chem.*, 2010, **58**, 2230–2238.
- 29 C. L. Lee, T. F. Kuo, J. J. Wang and T. M. Pan, *J. Neurosci. Res.*, 2007, **85**, 3171–3182.
- 30 D. Wild, G. Toth and H. U. Humpf, *J. Agric. Food Chem.*, 2002, **50**, 3999–4002.
- 31 S. Jongrungruangchok, P. Kittakoop, B. Yongsmith, R. Bavovada, S. Tanasupawat, N. Lartpornmatulee and Y. Thebtaranonth, *Phytochemistry*, 2004, **65**, 2569–2575.
- 32 Y. Zheng, Y. Xin and Y. Guo, *Food Chem.*, 2009, **113**, 705–711.
- 33 T. Akihisa, S. Mafune, M. Ukiya, Y. Kimura, K. Yasukawa, T. Suzuki, H. Tokuda, N. Tanabe and T. Fukuoka, *J. Nat. Prod.*, 2004, **67**, 479–480.
- 34 T. Akihisa, H. Tokuda, K. Yasukawa, M. Ukiya, A. Kiyota, N. Sakamoto, T. Suzuki, N. Tanabe and H. Nishino, *J. Agric. Food Chem.*, 2005, **53**, 562–565.
- 35 M. J. Cheng, M. D. Wu, I. S. Chen and G. F. Yuan, *Chem. Pharm. Bull.*, 2008, **56**, 394–397.
- 36 N. Osmanova, W. Schultze and N. Ayoub, *Phytochem. Rev.*, 2010, **9**, 315–342.
- 37 J. M. Gao, S. X. Yang and J. C. Qin, *Chem. Rev.*, 2013, **113**, 4755–4811.



38 K. Fassbender, M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, M. Hennerici, K. Beyreuther and T. Hartmann, *Proc. Natl. Acad. Sci. U. S. A.*, 2001, **98**, 5856–5861.

39 P. Salins, S. Shawesh, Y. He, A. Dibrov, T. Kashour, G. Arthur and F. Amara, *Neurosci. Lett.*, 2007, **412**, 211–216.

40 H. C. Huang and Z. F. Jiang, *Journal of Alzheimer's disease*, 2009, **16**, 15–27.

41 B. A. Yankner, *Neuron*, 1996, **16**, 921–932.

42 M. P. Mattson, *Nat. Rev. Mol. Cell Biol.*, 2000, **1**, 120–129.

43 A. Gella and N. Durany, *Cell Adhes. Migr.*, 2009, **3**, 88–93.

44 S. Miranda, C. Opazo, L. F. Larrondo, F. J. Munoz, F. Ruiz, F. Leighton and N. C. Inestrosa, *Prog. Neurobiol.*, 2000, **62**, 633–648.

45 A. H. Moore and M. K. O'Banion, *Adv. Drug Delivery Rev.*, 2002, **54**, 1627–1656.

46 E. M. Ribe, E. Serrano-Saiz, N. Akpan and C. M. Troy, *Biochem. J.*, 2008, **415**, 165–182.

47 I. Budihardjo, H. Oliver, M. Lutter, X. Luo and X. Wang, *Annu. Rev. Cell Dev. Biol.*, 1999, **15**, 269–290.

48 J. W. Allen, B. A. Eldadah, X. Huang, S. M. Knoblach and A. I. Faden, *J. Neurosci. Res.*, 2001, **65**, 45–53.

49 J. S. Wadia, R. M. Chalmers-Redman, W. J. Ju, G. W. Carlile, J. L. Phillips, A. D. Fraser and W. G. Tatton, *J. Neurosci.*, 1998, **18**, 932–947.

50 M. Orth and A. H. Schapira, *American journal of medical genetics*, 2001, **106**, 27–36.

51 K. Hirai, G. Aliev, A. Nunomura, H. Fujioka, R. L. Russell, C. S. Atwood, A. B. Johnson, Y. Kress, H. V. Vinters, M. Tabaton, S. Shimohama, A. D. Cash, S. L. Siedlak, P. L. Harris, P. K. Jones, R. B. Petersen, G. Perry and M. A. Smith, *J. Neurosci.*, 2001, **21**, 3017–3023.

52 Y. Morel and R. Barouki, *Biochem. J.*, 1999, **342**(Pt 3), 481–496.

53 D. J. Bonda, X. Wang, G. Perry, A. Nunomura, M. Tabaton, X. Zhu and M. A. Smith, *Neuropharmacology*, 2010, **59**, 290–294.

54 S. Chakrabarti, M. Sinha, I. G. Thakurta, P. Banerjee and M. Chattopadhyay, *Curr. Med. Chem.*, 2013, **20**, 4648–4664.

55 J. T. Coyle and P. Puttfarcken, *Science*, 1993, **262**, 689–695.

56 V. Contardo-Jara, A. Krueger, H. J. Exner and C. Wiegand, *J. Environ. Monit.*, 2009, **11**, 1147–1156.

57 X. Q. Xiao, R. Wang and X. C. Tang, *J. Neurosci. Res.*, 2000, **61**, 564–569.

58 P. Cohen, C. F. Holmes and Y. Tsukitani, *Trends Biochem. Sci.*, 1990, **15**, 98–102.

59 T. Arendt, M. Holzer, M. K. Bruckner, C. Janke and U. Gartner, *J. Neurosci.*, 1998, **85**, 1337–1340.

60 L. Amniai, P. Barbier, A. Sillen, J. M. Wierszeski, V. Peyrot, G. Lippens and I. Landrieu, *FASEB J.*, 2009, **23**, 1146–1152.

61 A. Lan, X. Liao, L. Mo, C. Yang, Z. Yang, X. Wang, F. Hu, P. Chen, J. Feng, D. Zheng and L. Xiao, Hydrogen Sulfide Protects against Chemical Hypoxia-Induced Injury by Inhibiting ROS-Activated ERK1/2 and p38MAPK Signaling Pathways in PC12 Cells, *PLoS One*, 2011, **6**, e25921.

